O‐glycan structures in apo(a) subunit of human lipoprotein(a) suppresses the pro‐angiogenic activity of galectin‐1 on human umbilical vein endothelial cells
The FASEB Journal · 2023
DOI: 10.1096/fj.202201001rr ↗Kurz gefasst
Fachartikel in der Zeitschrift The FASEB Journal, 2023. Verfasst von Vasantha Kalaivani und 4 weiteren Autor:innen. Beteiligte Einrichtung: Diabetes Biology Laboratory, Division of Cardiovascular Diseases and Diabetes Biology, Rajiv Gandhi Centre for Biotechnology, Thiruvananthapuram, Ind…. Hauptthemen laut MEDLINE: Galectin 1, Lipoprotein(a). Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 55 Literaturangaben. Gefördert von: Science and Engineering Research Board.
Abstract (Originalsprache)
Apolipoprotein(a) [apo(a)] is a highly polymorphic O‐glycoprotein circulating in human plasma as lipoprotein(a) [Lp(a)]. The O‐glycan structures of apo(a) subunit of Lp(a) serve as strong ligands of galectin‐1, an O‐glycan binding pro‐angiogenic lectin abundantly expressed in placental vascular tissues. But the pathophysiological significance of apo(a)‐galectin‐1 binding is not yet been revealed. Carbohydrate‐dependent binding of galectin‐1 to another O‐glycoprotein, neuropilin‐1 (NRP‐1) on endothelial cells activates vascular endothelial growth factor receptor 2 (VEGFR2) and mitogen‐activated protein kinase (MAPK) signaling. Using apo(a), isolated from human plasma, we demonstrated the potential of the O‐glycan structures of apo(a) in Lp(a) to inhibit angiogenic properties such as proliferation, migration, and tube‐formation in human umbilical vein endothelial cells (HUVECs) as well as neovascularization in chick chorioallantoic membrane. Further, in vitro protein‐protein interaction studies have confirmed apo(a) as a superior ligand to NRP‐1 for galectin‐1 binding. We also demonstrated that the protein levels of galectin‐1, NRP‐1, VEGFR2, and downstream proteins in MAPK signaling were reduced in HUVECs in the presence of apo(a) with intact O‐glycan structures compared to that of de‐O‐glycosylated apo(a). In conclusion, our study shows that apo(a)‐linked O‐glycans prevent the binding of galectin‐1 to NRP‐1 leading to the inhibition of galectin‐1/neuropilin‐1/VEGFR2/MAPK‐mediated angiogenic signaling pathway in endothelial cells. As higher plasma Lp(a) level in women is an independent risk factor for pre‐eclamsia, a pregnancy‐associated vascular complication, we propose that apo(a) O‐glycans‐mediated inhibition of the pro‐angiogenic activity of galectin‐1 may be one of the underlying molecular mechanism of pathogenesis of Lp(a) in pre‐eclampsia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Diabetes Biology Laboratory, Division of Cardiovascular Diseases and Diabetes Biology, Rajiv Gandhi Centre for Biotechnology, Thiruvananthapuram, India.
ORCID-Profile: Vasantha Kalaivani
Förderung
- Science and Engineering Research Board
Zitieren
APA
Kalaivani, V., Krishna, M. S., Kumar, A. A., Satheesh, G., & Jaleel, A. (2023). O‐glycan structures in apo(a) subunit of human lipoprotein(a) suppresses the pro‐angiogenic activity of galectin‐1 on human umbilical vein endothelial cells. The FASEB Journal. https://doi.org/10.1096/fj.202201001rr
Vancouver
Kalaivani V, Krishna MS, Kumar AA, Satheesh G, Jaleel A. O‐glycan structures in apo(a) subunit of human lipoprotein(a) suppresses the pro‐angiogenic activity of galectin‐1 on human umbilical vein endothelial cells. The FASEB Journal. 2023. doi:10.1096/fj.202201001rr
BibTeX
@article{Kalaivani2023,
author = {Kalaivani, Vasantha and Krishna, Mahesh S and Kumar, Asokan Aneesh and Satheesh, Gopika and Jaleel, Abdul},
title = {O‐glycan structures in apo(a) subunit of human lipoprotein(a) suppresses the pro‐angiogenic activity of galectin‐1 on human umbilical vein endothelial cells},
journal = {The FASEB Journal},
year = {2023},
doi = {10.1096/fj.202201001rr}
}
EUVIMED